1. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease
- Author
-
Federico J. Mensa, Fred Poordad, Tami Pilot-Matias, Magdy Elkhashab, Neddie Zadeikis, Albert Tran, Carolyn M. Setze, Catherine A.M. Stedman, Ariel Porcalla, Marcus A. Wörns, Yao Yu, Stanley Wang, Joaquin Mario Valdes, S. Greenbloom, T. Nguyen, C.-W. Lin, Jean-Pierre Mulkay, Armen Asatryan, Wei Liu, and Edward Gane
- Subjects
Cyclopropanes ,Liver Cirrhosis ,Male ,Aminoisobutyric Acids ,Pyrrolidines ,Cirrhosis ,Sustained Virologic Response ,adverse event ,Hepacivirus ,medicine.disease_cause ,Gastroenterology ,0302 clinical medicine ,030212 general & internal medicine ,Pathologie maladies infectieuses ,Sulfonamides ,medicine.diagnostic_test ,Liver Diseases ,Pibrentasvir ,Microbiologie et protistologie [entomologie,phytoparasitolog.] ,Infectious Diseases ,Data Interpretation, Statistical ,Liver biopsy ,glecaprevir/pibrentasvir ,HCV ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,compensated cirrhosis ,Microbiologie et protistologie [parasitologie hum. et anim.] ,Microbiology (medical) ,medicine.medical_specialty ,Genotype ,Proline ,Lactams, Macrocyclic ,Hepatitis C virus ,Antiviral Agents ,03 medical and health sciences ,Leucine ,Quinoxalines ,Internal medicine ,medicine ,Humans ,Adverse effect ,Aged ,business.industry ,Glecaprevir ,Hepatitis C, Chronic ,medicine.disease ,Benzimidazoles ,Microbiologie et protistologie [bacteriol.virolog.mycolog.] ,Transient elastography ,business ,chronic kidney disease ,Kidney disease - Abstract
Background: Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This integrated analysis reports the safety, efficacy, and pharmacokinetics (PK) of the ribavirin-free, direct-acting, antiviral, fixed-dose combination of glecaprevir/pibrentasvir (G/P) in patients with chronic HCV genotype 1-6 infections and compensated liver disease, including patients with chronic kidney disease stages 4 or 5 (CKD 4/5). Methods: Data from 9 Phase II and III clinical trials, assessing the efficacy and safety of G/P treatment for 8-16 weeks, were included. The presence of cirrhosis was determined at screening using a liver biopsy, transient elastography, or serum biomarkers. The objectives were to evaluate safety, the rate of sustained virologic response at post-treatment week 12 (SVR12), and steady-state PK by cirrhosis status. Results: Among 2369 patients, 308 (13%) were Child-Pugh Class A, including 20 with CKD 4/5. Overall, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2019